CONSUN PHARMA (01681) plans to carry out a share buyback program.

CONSUN PHARMA (01681) announced that the company has decided to implement a share buyback plan through a general mandate granted by the shareholders at the annual general meeting on May 26, 2026. The company will repurchase shares on the open market. The total available funds for the share buyback program will be up to HK$200 million. According to the Listing Rules of the Hong Kong Stock Exchange, the buyback price per share shall not exceed 5% above the average closing price of the shares for the five trading days immediately preceding each buyback. The board of directors is confident in the company's business development and prospects, and believes that the current share price does not fully reflect its intrinsic value or the value perceived by investors. The board believes that, depending on market conditions and financing arrangements at the time, the share buyback plan aligns with the company's long-term development strategy. Implementing the share buyback plan will optimize the management of the company's capital structure, serving the overall interests of the company and its shareholders.